{"nctId":"NCT00221195","briefTitle":"Efficacy Study of Activated Prothrombin Complex for Prevention of Bleeds in Hemophilia A With Inhibitors","startDateStruct":{"date":"2003-06"},"conditions":["Hemophilia A With Inhibitors"],"count":34,"armGroups":[{"label":"On-demand first","type":"OTHER","interventionNames":["Drug: activated prothrombin complex concentrate (FEIBA)"]},{"label":"Prophylaxis first","type":"OTHER","interventionNames":["Drug: activated prothrombin complex concentrate (FEIBA)"]}],"interventions":[{"name":"activated prothrombin complex concentrate (FEIBA)","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* hemophilia A, any severity, with documented history of high-titer inhibitor (\\>5BU); current use of bypassing agents (PCCs, aPCCs or rFVIIa) for treatment of bleeds; \\>/= 6 bleeds requiring bypassing therapy in the previous 6 months\n\nExclusion Criteria:\n\n* concomitant immune tolerance therapy; clinically symptomatic liver disease, platelet count less than 100,000","healthyVolunteers":false,"sex":"ALL","minimumAge":"24 Months","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Bleeds During 6 Month Treatment Period","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"13.1","spread":"7.1"},{"groupId":"OG001","value":"5.0","spread":"5.0"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":3,"n":31},"commonTop":["Pyrexia","Ecchymosis","Influenza","Pain","Cough"]}}}